Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CORT113176 (dazucorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor (GR), but does not bind to the body’s other hormone receptors and is being developed for amyotrophic lateral sclerosis (ALS).
Lead Product(s): Dazucorilant
Therapeutic Area: Neurology Product Name: CORT113176
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated for the treatment of adrenal cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Korlym (mifepristone) is a selective antagonist of the progesterone receptor at low doses and blocks the GR-II at higher doses. It is being evaluated for the treatment of cushing syndrome.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.
Lead Product(s): Mifepristone
Therapeutic Area: Endocrinology Product Name: Korlym
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed for the treatment of Non-Alcoholic Steatohepatitis.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
CORT118335 (miricorilant) is a potent, orally active non-steroidal glucocorticoid receptor (GR) antagonist that is being developed by Corcept Therapeutics.
Lead Product(s): Miricorilant
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CORT118335
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
DAZALS is a 198-patient, randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in patients with ALS. The primary endpoints will be ALS Functional Rating Scale-Revised (ALSFRS-R) total score and safety.
Lead Product(s): Dazucorilant
Therapeutic Area: Neurology Product Name: CORT113176
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Phase 2 trial showed that CORT-125134 (relacorilant) plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel alone.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT-125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
In Corcept’s Phase 2 trial, women who met the entry criteria for ROSELLA and received CORT-125134 (relacorilant) exhibited substantial benefit, without increasing the frequency or severity of adverse events.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT-125134
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022